Purpose. To evaluate our hospital protocol of lowdose vitamin K titration for preoperative warfarin reversal for early hip fracture surgery. Methods. Records of 16 men and 33 women aged 63 to 93 (mean, 81) years who were taking warfarin for atrial fibrillation (n=40), venous thromboembolism (n=9), cerebrovascular accident (n=3), and prosthetic heart valve (n=3) and underwent surgery for hip fractures were reviewed. The 3 patients with a prosthetic heart valve were deemed high risk for thromboembolism and the remainder low-risk. The international normalised ratio (INR) of patients was checked on admission and 6 hours after administration of vitamin K; an INR of <1.7 was considered safe for surgery.
101 000 per year by 2020 in the United Kingdom, 1 in which 1% of the population take warfarin 2 to reduce the risk of thromboembolism (atrial fibrillation, venous thromboembolic disease, stroke, or following cardiac valve surgery). 3 3.2% of hip fracture patients are taking warfarin on admission. 4 Early surgery for hip fractures significantly decreases morbidity (infections and pressure sores) and mortality. 1, [5] [6] [7] In patients with femoral neck fractures, the 30-day mortality is 8.2% after early surgery (within 48 hours) 6 and increases to 41% after delayed surgery (beyond 48 hours). 7 The Best Practice Tariff (BPT) recommends hip fracture surgery within 36 hours, 8 whereas the National Institute for Health and Care Excellence (NICE) recommends surgery within 48 hours. 1 Strategies for warfarin reversal include omitting warfarin and administrating oral or intravenous vitamin K, fresh frozen plasma (FFP), or prothrombin complex concentrates (PCC). 9 Omitting warfarin slowly reduces the international normalised ratio (INR) to a safe level over 5 to 7 days. 10, 11 A more proactive pharmacological option is needed to reduce the INR to a safe level within 36 to 48 hours. 12, 13 Administrating vitamin K reduces surgical delay by 44 hours, without increasing the complication rate.
14 However, vitamin K may lead to inconsistent postoperative rewarfarinisation regimens and cause morbidity and increased length of hospital stay. 14 According to the NICE guidelines, 1 rapid safe reversal of warfarin is a priority for timely surgery and improved outcome, while reducing complications and length of hospital stay. This study evaluated our hospital protocol of low-dose vitamin K titration for warfarin reversal for early hip fracture surgery.
Materials and Methods
Records of 16 men and 33 women aged 63 to 93 (mean, 81) years who were taking warfarin for atrial fibrillation (n=40), venous thromboembolism (n=9), cerebrovascular accident (n=3), and prosthetic heart valve (n=3) and underwent hemiarthroplasty for intracapsular hip fractures (n=29) or dynamic hip screw fixation for extracapsular hip fractures (n=20) between May 2010 and February 2012 were reviewed. Patients with a prosthetic heart valve were at high risk for thromboembolism, whereas patients with atrial fibrillation, venous thromboembolism, or cerebrovascular accident were at low risk.
Our hospital protocol for warfarin reversal was devised by 2 anaesthetic consultants, an orthogeriatric consultant, and an orthopaedic consultant, in conjunction with haematologists. The INR was checked on admission and 6 hours after administration of vitamin K; an INR of <1.7 was considered safe for surgery. Low-risk patients received low-dose (2 mg) intravenous vitamin K every 6 hours from admission until the INR was <1.7. High-risk patients discontinued warfarin use and received bridging therapy with a heparin infusion until their INR was <1.7.
results
For the 46 low-risk patients, the mean INR on admission was 2.6 (range, 1.1-4.6) [in 4 patients it was <1.7] and decreased to <1.7 after a mean of 2.2 (range, 0-4) administrations of 2 mg of vitamin K. Their INR was <1.7 within 18 hours (mean, 14 hours), and their last INR before surgery was ≤1.5 in 67% and 1.6 to 1.7 in 33%. 78% and 84% of patients underwent surgery within 36 and 48 hours, respectively. This is in keeping with the 2012 national average of 83% undergoing surgery within 48 hours. 15 In the 22% of patients who did not undergo surgery within 36 hours, the delay was due to insufficient operative time or the patient being medically unfit for surgery. The 3 high-risk patients underwent bridging therapy of low-molecular-weight heparin and received no vitamin K; their mean INR on admission was 3.2 (range, 3.1-3.3) and the mean time to surgery was 5.3 (range, 3-8) days.
Two low-risk patients and one high-risk patient died within 5 days of surgery from myocardial infarction (n=1) or pneumonia with respiratory failure (n=2) before the therapeutic INR range was reached. Two patients were advised to stop warfarin by an orthogeriatrician. The remaining 44 patients restarted their usual dose of warfarin within 24 hours of surgery; 65% reached their therapeutic INR range by day 7, and 85% by day 14. Ten patients were discharged to community anticoagulation services for a mean of 7.7 (range, 5-11) days and received low-molecular-weight heparin. Excluding these 10 patients, 85% reached their therapeutic INR range by day 7 and 97% by day 14. For the 3 high-risk patients, one reached the therapeutic INR range after one day and stayed in hospital for 27 days, one after 5 days and stayed for 257 days, and one died on day 3. Overall, the mean length of hospital stay was 18 (range, 2-124) days. No patient developed venous thromboembolism within one year. The 30-day and one-year mortality was 8.2% and 32.6%, respectively.
discussion
According to the National Hip Fracture database, 15 the mean age of hip fracture patients is 77 years and the male-to-female ratio is 1:3. The mean age of our patients was 81.2 years and the male-to-female ratio was 1:2. Increasing age is a risk factor for atrial fibrillation. In our hospital, the 30-day mortality was 4.1% for all hip fracture patients and 8.2% for those taking warfarin; both rates are lower than the national average of 8.4%.
15
In up to 11% of hip fracture patients on warfarin, surgery is delayed beyond 48 hours because the INR is >1.6. 16 An INR of >1.7 increases the risk of perioperative bleeding and limits anaesthetic options, as regional anaesthesia is contraindicated. 17 The safe INR of <1.7 in our hospital is higher than the suggested <1.5 for major surgery, 18 as the INR will continue to decrease after administration of vitamin K. Warfarin induces vitamin K deficiency in cells by blocking the action of vitamin K epoxide reductase. This leads to production of clotting factors with inadequate gamma-carboxyglutamate and hence limits formation of clot during tissue injury. Administration of vitamin K reverses the deficiency in cells and promotes clotting. We recommend the use of 1 g of intravenous tranexamic acid during anaesthesia to stabilise these pre-existing clots due to fibrinolytic activity blockade, making regional anaesthesia an option. 17 Patients who required 2 doses of intravenous vitamin K may have had resistance to vitamin K reversal, owing to consumptive coagulopathy associated with the hip fracture. In uninjured patients with a high INR, lower doses are usually effective within 12 hours. 11, 19 The British Committee for Standards in Haematology recommends intravenous administration of 1 to 3 mg of vitamin K for warfarin reversal for emergency surgery. 11 When expedition of surgery within 6 to 12 hours is needed, administration of PCC and intravenous vitamin K are advocated.
11
The mean time to reach safe INR is 4 days after oral vitamin K 4,12,20-22 and 2 days after intravenous vitamin K.
4 A large dose (5-10 mg) is effective in lowering the INR to a safe level (mean time to surgery, 30.5 hours), 4 but is associated with allergic reactions and postoperative warfarin resistance, which is not seen with a smaller dose (1-3 mg). 23 FFP or PCC targets other parts of the clotting cascade unaffected by warfarin and avoids postoperative warfarin resistance. 24 Nonetheless, PCC may increase the risk of thrombogenic events (stroke, myocardial infarction, venous thromboembolism, and disseminated intravascular coagulation). 24 The disadvantages of using FFP or PCC include storage, timing of administration, thawing (for FFP), the need to undergo surgery within 4 to 8 hours of administration, and the risk of transfusionrelated acute lung injury, anaphylaxis, infection, and alloimmunisation. 25 In addition, a large fluid volume is required and may cause cardiac problems in patients who take warfarin for a cardiac comorbidity. Furthermore, 2 mg of vitamin K (38p) is much less expensive than FFP (£28 per unit) or PCC (£858 per treatment).
In our patients, the mean duration out of therapeutic range was 9 (range, 1-25) days; bridging therapy using low-molecular-weight heparin reduced the risk of thromboembolism in high-risk patients. 12, 19 The absolute risk of thromboembolic events for 7-day interruption of warfarin in highrisk patients is 0.3%; the relative risk in low-risk patients decreases 10-fold. 4, 26 Consultation with haematologists, cardiologists, and cardiothoracic surgeons for bridging therapy is recommended. Patients can be discharged with a sub-therapeutic INR if they receive low-molecular-weight heparin until their INR is within target range. This may reduce the length of hospital stay and warrants further investigation.
conclusion
The low-dose intravenous vitamin K protocol is safe and effective in reversing warfarin within 18 hours. Hip fracture surgery within 36 to 48 hours of admission improves morbidity and mortality.
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